Business Wire

New Data From Conviva Identifies Which Brands Have Successfully Cracked the TikTok Algorithm to Achieve Significant Gains

28.4.2022 20:53:00 EEST | Business Wire | Press release

Share

Conviva, the continuous measurement analytics platform for streaming media, released its third annual TikTok Benchmarks & Strategy Guide today, examining more than 1500 verified brand accounts on TikTok, with a combined 1.42 billion followers and 591,000 posted videos. The report details which brands are most effectively capitalizing on the pandemic-fueled increased popularity of TikTok and highlights how the most successful brands were able to add an average of 527,000 new followers from March 2021 to March 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428006098/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. (Graphic: Business Wire)

“At the beginning of the pandemic, many brands were still hesitant to fully embrace TikTok as a powerful tool in their marketing strategy. However, over the last 18 months TikTok’s growth and popularity has exploded—and brands are racing to build and execute a strategy to tap into this massive incremental audience,” said Nick Cicero, VP of Strategy, Conviva. “With no signs of slowing down, it’s important for brands to understand what tactics—namely consistently posting quality content—actually move the needle in terms of engagement and brand building on TikTok.”

Across the industries measured by Conviva, sports leagues’ accounts achieved the largest average annual increase of followers at 969,800, followed by sports media at 825,000. Four TikTok accounts—Tottenham Hotspur, Champions League, Manchester United and Netflix—all increased their following by more than 10 million followers in the last year. ESPN was close behind with an increase of 9.1 million followers. Sports leagues also edged out sports media accounts to become the fastest growing segment of 2021.

As many brands have come to realize in the last year, Conviva’s research shows that posting consistently makes a significant difference when building a TikTok following. Of the 1500 brand accounts measured, accounts posted, on average, 189 times in the past year, a 13% increase from last year’s average. Additionally, among the top 20 accounts ranked by follower growth, those accounts averaged roughly 7.1 times more posts over the past year than all accounts, on average. For top performers, that amounts to around three to four posts per day, up from two to three times per day from last year’s report.

Recognizing that engagement has become an important metric for brands, Conviva added an average engagement rate ranking to this year’s report. According to Conviva data, the average engagement rate for brands with under 100,000 followers is incredibly high at 28%, demonstrating TikTok’s well-honed ability to offer new accounts the organic reach they need to build a following. However, as follower counts go up, engagement rates typically go down. For example, Family Feud, an account notoriously popular for its reshared audio tracks, took the top spot for accounts with over 1 million followers with an engagement rate of 41.6%.

Other findings include:

  • Of the nine sports leagues analyzed, teams in the Premier League had the highest average number of followers at 3.2 million, followed by Ligue 1 at 2.1 million and La Liga at 1.7 million. European futbol teams dominated the fastest growing accounts list with eight European teams in the top 20.
  • The most-followed US sports teams were the Golden State Warriors at 3.7 million, the Kansas City Chiefs at 2 million and Dallas Cowboys at 1.7m. The Chiefs, Cowboys and the Warriors were the only American teams in the top 25.
  • Guinness World Records maintained its spot at the top of the brands list with 19.1 million followers.
  • Overall, engagement rate rankings were dominated by TV and entertainment accounts. Those accounts enjoyed the highest average shares, comments and likes per video.
  • Within the brands ranking, gaming showed up big this year as Roblox and Fortnite claimed the No. 2 and 3 spots at 7.9 million and 7.7 million, respectively.
  • WWE overtook NBA as the most-followed sports league.

In addition to offering the latest benchmark data, Conviva also shares specific forward-looking trends to employ to achieve TikTok success in 2022. Businesses interested in utilizing these strategies and learning more about emerging social media platforms can download Conviva’s TikTok Benchmarks & Strategy Guide here: https://www.conviva.com/state-of-streaming/convivas-2022-tiktok-benchmarks-strategy-guide-for-brands

About Conviva Social Insights

Conviva Social Insights provides the world’s leading publishers, brands and sports organizations with comprehensive cross-platform social media analytics across the entire social universe (Facebook, Instagram, Twitter, TikTok, Snapchat and YouTube), making it easy to discover what accounts, posts, and videos are performing the best and analyze why. Social Insights also offers a customizable leaderboard and research tool for monitoring the performance of brand and streamed videos, enabling marketers to target campaigns and maximize ROI. To learn more, visit https://www.conviva.com/social-insights/.

About Conviva

Conviva helps streaming businesses act within seconds of observation to grow their business ahead of competition. Conviva’s Continuous Measurement Analytics platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. Using just a single sensor and a single pipeline, our 58 patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Megan Dobransky
mdobransky@conviva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye